Entering text into the input field will update the search result below

Marinus Pharma's ganaxolone shows seizure-reducing effect in 11-subject epilepsy study; investors unimpressed, shares down 5% premarket

  • Nano cap Marinus Pharmaceuticals (NASDAQ:MRNS) eases 5% premarket on robust volume in response to its announcement of top-line results from a small exploratory open-label study of GABA modulator ganaxolone in females with PCDH19 pediatric epilepsy, an Orphan Drug designation by the FDA.
  • 64% (n=7/11) of patients experienced a reduction in seizures from baseline with 54% of the responders (n=4/7) showing a reduction greater than 50%.
  • 73% (n=8/11) experienced an increase in seizure-free days.
  • The trial evaluated ganaxolone as adjunctive treatment, administered as oral liquid suspension or capsules, for 26 weeks after establishing baseline seizure frequency up to 12 weeks.
  • Ganaxolone is a small molecule inhibitor of the neurotransmitter GABA, which helps control epileptic seizures.

Recommended For You

About MRNS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRNS--
Marinus Pharmaceuticals, Inc.